Search research articles
Contact Us
Filters
Showing results (171-180 of 276) with videos related to
Page
of 28
Sort By:
Hematological Oncology
|
April 22, 2023
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
Brian A Jonas, Jing-Zhou Hou, Gail J Roboz, et al.
Blood
|
August 12, 2022
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
Hartmut Döhner, Andrew H Wei, Gail J Roboz, et al.
Blood
|
February 1, 2007
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Francois Guilhot, Jane Apperley, Dong-Wook Kim, et al.
Leukemia Research
|
January 19, 2016
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents
Aziz Nazha, Mikkael A Sekeres, Guillermo Garcia-Manero, et al.
Leukemia & Lymphoma
|
December 20, 2021
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes
Gail J Roboz, Karen Yee, Amit Verma, et al.
Haematologica
|
March 20, 2016
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure
Aziz Nazha, Rami S Komrokji, Guillermo Garcia-Manero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2016
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
Eric Padron, Amy Dezern, Marcio Andrade-Campos, et al.
British Journal of Haematology
|
June 17, 2025
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies
Michael R Savona, Olatoyosi Odenike, Gail J Roboz, et al.
Frontiers in Oncology
|
September 16, 2021
Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML
Amanda Lopez, Sanjay Patel, Julia T Geyer, et al.
Blood Advances
|
April 25, 2020
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia
Catherine C Smith, Mark J Levis, Olga Frankfurt, et al.
Page
of 28
Search research articles
Search
Showing results (171-180 of 276) with videos related to
Sort By:
Page
of 28
Hematological Oncology
|
April 22, 2023
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
Brian A Jonas, Jing-Zhou Hou, Gail J Roboz, et al.
Blood
|
August 12, 2022
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
Hartmut Döhner, Andrew H Wei, Gail J Roboz, et al.
Blood
|
February 1, 2007
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Francois Guilhot, Jane Apperley, Dong-Wook Kim, et al.
Leukemia Research
|
January 19, 2016
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents
Aziz Nazha, Mikkael A Sekeres, Guillermo Garcia-Manero, et al.
Leukemia & Lymphoma
|
December 20, 2021
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes
Gail J Roboz, Karen Yee, Amit Verma, et al.
Haematologica
|
March 20, 2016
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure
Aziz Nazha, Rami S Komrokji, Guillermo Garcia-Manero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2016
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
Eric Padron, Amy Dezern, Marcio Andrade-Campos, et al.
British Journal of Haematology
|
June 17, 2025
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies
Michael R Savona, Olatoyosi Odenike, Gail J Roboz, et al.
Frontiers in Oncology
|
September 16, 2021
Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML
Amanda Lopez, Sanjay Patel, Julia T Geyer, et al.
Blood Advances
|
April 25, 2020
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia
Catherine C Smith, Mark J Levis, Olga Frankfurt, et al.
Page
of 28